RELB and diffuse large B-cell lymphoma: Besides, RelB was reported to confer DLBCL cell resistance to DNA damage-induced apoptosis in response to doxorubicin and RelB positivity was correlated with high expression of cellular inhibitor of apoptosis protein (clAP2) (Eluard et al., 2022).